Cleared Traditional

K840210 - REPTILASE-R HA35

K840210 is the FDA 510(k) clearance for REPTILASE-R HA35 by Wellcome Diagnostics. It is a Class 2 Hematology device (product code JCO) cleared through the Traditional 510(k) pathway after a 95-day FDA review.

K840210 · Wellcome Diagnostics · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1984
Decision
95d
Days
Class 2
Risk

K840210 is an FDA 510(k) clearance for the REPTILASE-R HA35. Classified as Bothrops Atrox Reagent (product code JCO), Class II - Special Controls.

Submitted by Wellcome Diagnostics (Mchenry, US). The FDA issued a Cleared decision on April 23, 1984 after a review of 95 days - within the typical 510(k) review window.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.8100 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Wellcome Diagnostics devices

Submission Details

510(k) Number K840210 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 19, 1984
Decision Date April 23, 1984
Days to Decision 95 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
18d faster than avg
Panel avg: 113d · This submission: 95d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JCO Bothrops Atrox Reagent
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.8100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.